Comparative Evaluation of Subgingivally Delivered Titanium Prepared Platelet Rich Fibrin (T-PRF) and Tetracycline Fibers as an Adjunct to Scaling and Root Planning in Treatment of Periodontitis: A Randomized Controlled Clinical Trial Authors: Chirag Gupta, Swati Agarwal, Ellora Madan, Kratee Sharma, Nuzla Agha, Karnika Agrawal Published: 2025 ABSTRACT Aim:The present study aimed to evaluate and compare the clinical effectiveness of subgingivally delivered T-PRF with subgingivally delivered tetracycline fibers over scaling and root planning in patients with periodontitis.Materials and Methods:This single-center, randomized controlled clinical trial enrolled patients aged 18–65 years with chronic periodontitis and at least three non-adjacent periodontal pockets of ≥5 mm and ≤10 mm. Seventy-five sites were randomly allocated to three groups: Group A (SRP alone with saline irrigation), Group B (SRP with subgingival administration of T-PRF), and Group C (SRP with subgingival placement of tetracycline fibers). Clinical parameters (PI, mSBI, PPD, RAL) were recorded at baseline, 1 week, and 3 months using calibrated examiners and standardized methods, including customised acrylic occlusal stents and a UNC 15 probe. Intragroup and intergroup comparisons of clinical parameters were performed using appropriate statistical tests.Results:Intragroup analysis showed statistically significant reductions in PI, mSBI, and PPD, and a significant gain in RAL in all three groups from baseline to 3 months (P < 0.01). Intergroup comparisons at baseline were not significant for all parameters. At 3 months, mSBI and PPD showed significant differences between groups, with Group C (Tetracycline fibers) generally demonstrating the greatest improvement, although post-hoc analysis revealed specific significant differences between Group A and Group C for mSBI and PPD.Conclusion:Both subgingivally delivered T-PRF and tetracycline fibers as adjuncts to SRP resulted in significant clinical improvements in patients with chronic periodontitis. INTRODUCTION Periodontal disease (PD) is a chronic immune-mediated inflammatory condition marked by the destruction of the soft tissue attachment and supporting alveolar bone, leading to periodontal pocket formation and/or gingival recession.[1] It results from microbial colonization by pathogenic microorganisms and, if untreated, can cause tooth mobility, displacement, and eventual loss, thereby impairing mastication, nutrition, and overall health. Management options include nonsurgical therapies such as scaling and root planning (SRP), adjunctive antimicrobial therapy, and surgical interventions. SRP is considered the gold standard for nonsurgical management of chronic periodontitis[2]; however, its effectiveness can be limited in eradicating pathogens from deep pockets, furcations, and inaccessible areas, contributing to high recurrence rates.[34] To enhance SRP outcomes, adjunctive antimicrobial approaches—particularly local drug delivery (LDD)—are utilized to achieve high concentrations at the site of infection with minimal systemic exposure.[35] LDD is valued for its ability to modify subgingival flora, reduce systemic toxicity risk, and improve patient compliance. Among various LDD agents, tetracycline has been extensively employed for its bacteriostatic action, broad-spectrum activity, inhibition of bone resorption, anti-inflammatory effects, and promotion of fibroblast function.[5] Advances in delivery methods, such as bioresorbable collagen-based tetracycline fibers, have improved ease of placement, retention, and local therapeutic effect, offering a simple and effective adjunct to conventional periodontal therapy.[6] MATERIALS AND METHODS This single-center, full-mouth randomized controlled trial with a 1:1 allocation was conducted in the Department of Periodontology, Kothiwal Dental College and Research Centre, Moradabad, after obtaining ethical approval and written informed consent from all participants. Eligible subjects were 18–65 years old, diagnosed with chronic periodontitis, and had at least three non-adjacent periodontal pockets measuring ≥5 mm and ≤10 mm. Exclusion criteria included recent antibiotic or periodontal therapy, systemic diseases, pregnancy, lactation, tobacco use, allergies to tetracycline or aloe vera, and use of certain medications. No adverse events were reported during the study. Participants were randomly allocated into three groups: Group A (scaling and root planning [SRP] only), Group B (SRP + titanium-prepared platelet-rich fibrin [T-PRF]), and Group C (SRP + tetracycline fibers). Clinical parameters recorded at baseline, 1 week, and 3 months included plaque index, modified sulcular bleeding index, probing pocket depth, and relative attachment level, measured using customized acrylic stents with UNC-15 probes. Stents were fabricated from self-cure resin to provide standardized measurement reference points. Following SRP, Group B sites received subgingival placement of T-PRF membranes, and Group C sites received tetracycline fibers, both inserted with curettes and covered with a periodontal pack. Group A received no adjunctive therapy. Post-procedure, patients were advised to avoid hard or sticky foods and oral hygiene in the treated area for 24 hours. Follow-ups at 1 week and 3 months were conducted to reassess all clinical parameters. Data were analyzed using one-way ANOVA with post-hoc Tukey tests for intergroup comparisons and paired t-tests for intragroup changes, with P < 0.05 considered statistically significant. RESULTS The intragroup comparison within the groups was statistically highly significant for all the clinical parameters from baseline to 3 months. A significant reduction in PI was seen in all groups over 3 months (P < 0.001), whereas no significant intergroup differences were observed post-treatment. For mSBI, significant intragroup improvements in all groups were noted and at 3 months, Group C (tetracycline) achieved a significantly greater reduction compared to Group A (P = 0.020). All groups showed significant reductions in PPD on intragroup comparisons. The greatest reduction was observed in Group C, with a significant difference between the A and C Groups (P = 0.010). For the RAL, significant intragroup gains were observed in all groups, with no statistically significant intergroup differences [Tables 1-3]. Table 1Intergroup comparison of clinical parameters in subjects of Group A and Group B at baseline and 3 months post interventionParametersTime intervalGroup A Mean±SDGroup B Mean±SD P PPDBaseline5.60±0.705.72±0.730.8673 months4.64±0.864.20±0.760.771RALBaseline10.64±1.7510.56±1.580.9873 months9.60±1.919.04±1.830.585PIBaseline3.64±0.433.49±0.500.5113 months1.65±0.271.59±0.230.637mSBIBaseline1.80±0.701.92±0.570.5113 months0.76±0.770.64±0.560.771 Intergroup comparison of clinical parameters in subjects of Group A and Group B at baseline and 3 months post intervention Table 2Intergroup comparison of clinical parameters in subjects of Group A and Group C at baseline and 3 months post interventionParametersTime intervalGroup A Mean±SDGroup C Mean±SD P PPDBaseline5.60±0.706.04±1.020.1563 months4.64±0.863.92±0.900.010RALBaseline10.64±1.7510.64±2.071.0003 months9.60±1.918.52±2.220.143PIBaseline3.64±0.433.45±0.450.3403 months1.65±0.271.48±0.250.058mSBIBaseline1.80±0.701.80±0.500.3403 months0.76±0.770.28±0.450.020 Intergroup comparison of clinical parameters in subjects of Group A and Group C at baseline and 3 months post intervention Table 3Intergroup comparison of clinical parameters in subjects of Group B and Group C at baseline and 3 months post interventionParametersTime intervalGroup B Mean±SDGroup C Mean±SD P PPDBaseline5.72±0.736.04±1.020.3683 months4.20±0.763.92±0.900.104RALBaseline10.56±1.5810.64±2.070.9873 months9.04±1.838.52±2.220.629PIBaseline3.49±0.503.45±0.450.0403 months1.59±0.231.48±0.250.334mSBIBaseline1.92±0.571.80±0.500.9513 months0.64±0.560.28±0.450.104 Intergroup comparison of clinical parameters in subjects of Group B and Group C at baseline and 3 months post intervention DISCUSSION Periodontal diseases, particularly chronic periodontitis, are common inflammatory disorders that progressively destroy tooth-supporting structures, leading to tooth mobility and eventual loss.[1] While the primary cause is persistent infection by pathogenic oral microorganisms, disease severity and progression are largely influenced by the host’s immune-inflammatory response. Scaling and root planning (SRP) remains the gold standard for non-surgical periodontal therapy, significantly improving clinical indices.[2] However, SRP alone may be insufficient to eliminate pathogens from deep pockets, furcations, and inaccessible biofilm-retentive areas, prompting the use of adjunctive local drug delivery (LDD) systems.[3] Adjunctive LDD agents such as chlorhexidine gel, metronidazole gel, and tetracycline fibers have demonstrated enhanced clinical outcomes when used with SRP.[4] Tetracycline fibers not only improve pocket depth reduction but also target key periodontopathogens including P. gingivalis, F. nucleatum, P. intermedia, E. corrodens, W. recta, and A. actinomycetemcomitans at concentrations achievable within the periodontal pocket.[56] Autologous platelet concentrates, particularly titanium-prepared platelet-rich fibrin (T-PRF), have emerged as promising regenerative adjuncts. Compared to standard PRF, T-PRF offers a denser fibrin matrix, prolonged resorption time, and sustained release of growth factors essential for healing.[7] Evidence from meta-analyses supports the efficacy of T-PRF in correcting both hard and soft tissue defects, highlighting its regenerative potential.[8] Despite strong individual benefits of both tetracycline fibers and T-PRF, there is a paucity of comparative studies directly assessing their relative effectiveness in periodontal regeneration. CONCLUSION Subgingival application of both T-PRF and tetracycline fibers as adjuncts to SRP significantly improved periodontal health in chronic periodontitis. Tetracycline fibers offered marginally superior results in some clinical measures; however, T-PRF remains a viable bioregenerative adjunct. Further long-term, multicenter studies are recommended. Conflicts of interest There are no conflicts of interest.